L. Ashley Blackshaw

L. Ashley Blackshaw

Auto-generated profile, based on publicly available information

L. Ashley Blackshaw

Centre for Neuroscience & Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in Gastroenterology
Verified
Journal Article
Closed access
Stuart BrierleyStuart Brierley
Stuart Brierley
RJR.CArter W. Jones
R.CArter W. Jones
GGGerald F. Gebhart
Gerald F. Gebhart
LBL.AShley Blackshaw
L.AShley Blackshaw

1 December 2013 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JCJoel Castro
Joel Castro
AHAndrea Harrington
Andrea Harrington
PHPatrick Hughes
Patrick Hughes
CMChristopher M. Martin
Christopher M. Martin
PGPei Ge
Pei Ge
Stuart BrierleyStuart Brierley
Stuart Brierley
Background & Aims Linaclotide is a minimally absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C). Little is known about the mechanism by which linaclotide reduces abdominal pain in patients with IBS-C. Methods We determined the effects of linaclotide on colonic sensory afferents in healthy mice and those with chronic visceral hypersensitivity. We assessed pain transmission by measuring activation of dorsal horn neurons in the spinal cord in response to noxious colorectal distention. Levels of Gucy2c messenger RNA were measured in tissues from mice using quantitative reverse transcription polymerase chain reaction and in situ hybridization. We used human intestinal cell lines to measure release of cyclic guanosine-3′,5′-monophosphate (cGMP) by linaclotide. We performed a post-hoc analysis of data from a phase III, double-blind, parallel-group study in which 805 patients with IBS-C were randomly assigned to groups given an oral placebo or 290 μg linaclotide once daily for 26 weeks. We quantified changes in IBS-C symptoms, including abdominal pain. Results In mice, linaclotide inhibited colonic nociceptors with greater efficacy during chronic visceral hypersensitivity. Intra-colonic administration of linaclotide reduced signaling of noxious colorectal distention to the spinal cord. The colonic mucosa, but not neurons, was found to express linaclotide's target, GC-C. The downstream effector of GC-C, cGMP, was released after administration of linaclotide and also inhibited nociceptors. The effects of linaclotide were lost in Gucy2c−/− mice and prevented by inhibiting cGMP transporters or removing the mucosa. During 26 weeks of linaclotide administration, a significantly greater percentage of patients (70%) had at least a 30% reduction in abdominal pain compared with patients given placebo (50%). Conclusions We have identified an analgesic mechanism of linaclotide: it activates GC-C expressed on mucosal epithelial cells, resulting in the production and release of cGMP. This extracellular cGMP acts on and inhibits nociceptors, thereby reducing nociception. We also found that linaclotide reduces chronic abdominal pain in patients with IBS-C.

1 October 2005 in Gut
Verified
Journal Article
Open access
PDF file
Amanda PageAmanda Page
Amanda Page
Stuart BrierleyStuart Brierley
Stuart Brierley
CMC M Martin
C M Martin
MPM P Price
M P Price
ESE Symonds
E Symonds
LBL A Blackshaw
L A Blackshaw
Aims: Members of the acid sensing ion channel (ASIC) family are strong candidates as mechanical transducers in sensory function. The authors have shown that ASIC1a has no role in skin but a clear influence in gastrointestinal mechanotransduction. Here they investigate further ASIC1a in gut mechanoreceptors, and compare its influence with ASIC2 and ASIC3. Methods and results: Expression of ASIC1a, 2, and 3 mRNA was found in vagal (nodose) and dorsal root ganglia (DRG), and was lost in mice lacking the respective genes. Recordings of different classes of splanchnic colonic afferents and vagal gastro-oesophageal afferents revealed that disruption of ASIC1a increased the mechanical sensitivity of all afferents in both locations. Disruption of ASIC2 had varied effects: increased mechanosensitivity in gastro-oesophageal mucosal endings, decreases in gastro-oesophageal tension receptors, increases in colonic serosal endings, and no change in colonic mesenteric endings. In ASIC3-/- mice, all afferent classes had markedly reduced mechanosensitivity except gastro-oesophageal mucosal receptors. Observations of gastric emptying and faecal output confirmed that increases in mechanosensitivity translate to changes in digestive function in conscious animals. Conclusions: These data show that ASIC3 makes a critical positive contribution to mechanosensitivity in three out of four classes of visceral afferents. The presence of ASIC1a appears to provide an inhibitory contribution to the ion channel complex, whereas the role of ASIC2 differs widely across subclasses of afferents. These findings contrast sharply with the effects of ASIC1, 2, and 3 in skin, suggesting that targeting these subunits with pharmacological agents may have different and more pronounced effects on mechanosensitivity in the viscera.

3 January 2007 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
LBL. A. Blackshaw
L. A. Blackshaw
SBS. J. H. Brookes
S. J. H. Brookes
DGD. Grundy
D. Grundy
MSM. Schemann
M. Schemann

6 April 2004 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
HBHans-Rudolf Berthoud
Hans-Rudolf Berthoud
LBL. A. Blackshaw
L. A. Blackshaw
SBS. J. H. Brookes
S. J. H. Brookes
DGD. Grundy
D. Grundy

1 June 2008 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Stuart BrierleyStuart Brierley
Stuart Brierley
Amanda PageAmanda Page
Amanda Page
PHPatrick Hughes
Patrick Hughes
BABirgit Adam
Birgit Adam
TLTobias Liebregts
Tobias Liebregts
LBL. Ashley Blackshaw
L. Ashley Blackshaw